REFRACTORY NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope to tame CAR-T's dangerous brain side effects
Disease control CompletedThis study tested whether adding a drug called anakinra to a powerful cell therapy (CAR-T) could reduce severe brain-related side effects in patients with lymphoma that has returned or resisted treatment. The main goal was to see if this combination made the CAR-T treatment safer…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: Marcela V. Maus, M.D.,Ph.D. • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New combo therapy tested for aggressive lymphomas
Disease control CompletedThis early-stage trial tested a new combination of two immune-based drugs, lenalidomide and blinatumomab, for adults with non-Hodgkin lymphoma that has come back or stopped responding to other treatments. The main goal was to find the safest dose and understand the side effects. …
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 30, 2026 14:28 UTC
-
New combo attack on Tough-to-Treat cancers
Disease control CompletedThis study tested whether combining a type of immunotherapy (pembrolizumab) with targeted radiation could help patients whose aggressive non-Hodgkin lymphoma had come back or stopped responding to other treatments. The goal was to see if the combination could shrink tumors and co…
Matched conditions: REFRACTORY NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC